



ASX / Media Release
30 November 2023

Payment of Capital Return Proceeds

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) today provides an update to shareholders of the Company in relation to the upcoming General Meeting on 5 December 2023 to approve a \$14.0 million equal access capital return.

If approved, Invex will be processing the capital return with the Record Date for eligible shareholders as at 5.00pm WST (Perth time) on Monday, 11 December 2023.

A shareholder of Invex on the Record Date will be entitled to receive the capital return. If shareholders have not provided the Invex share registry (Automic) with banking details and to avoid the capital return payment being withheld, shareholders will need to register banking details with Automic prior to the payment date of 18 December 2023.

In order to update banking details, please visit Automic's online Investor Portal at: <https://investor.automic.com.au/#/home>

Investors can access their account by logging in using their existing username and password - if investors do not have an existing username and password click "register". Once successfully logged in, click on "Profile" to provide banking details.

Alternatively, shareholders can complete and return a Direct Credit Facility form (see attachment). Investors will need their SRN/HIN (Securityholder Reference Number/Holder Identification Number) to complete the form.

If shareholders have any problems accessing account information, please contact Automic share registry on 1300 288 664 (or on +61 (0) 2 9698 5414 if calling from outside or Australia) or email at hello@automic.com.au.

- ENDS -

This release dated 30 November 2023 has been authorised for lodgement to ASX by Dr Thomas Duthy, Executive Director.

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

Use a black pen. Print in CAPITAL letters inside the boxes

--

[illegible]

Post Code



GPO Box 5193, Sydney, NSW 2001
P +61 (0)2 9698 5414 | F +61 (0)2 8583 3040
E hello@automic.com.au | ABN 27152260814

Securityholder Reference Number
or Holder Identification Number

You are required to insert this number

ASX Code

This form must be forwarded to Automatic Registry Services.

A REQUEST FOR DIRECT CREDITING OF PAYMENTS

BSB Number

Account Number

Name in which account is held (eg: John Smith)

[illegible]

Name of Australian bank or financial institution

Name of branch or suburb or town

Type of account (eg: cheque, savings)

Email address for electronic communications



DO NOT USE YOUR CARD NUMBER

If you are unsure of your account or BSB number, please check with your bank, building society or credit union.

B SIGN HERE - THIS SECTION MUST BE SIGNED FOR YOUR INSTRUCTIONS TO BE EXECUTED

Individual or Securityholder 1

Sole Director or
Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

--	--

Director/Company Secretary

Individual: This form is to be signed by the security holder.

Joint Holding: Where the holding is in more than one name, all of the securityholders must sign

Power of Attorney: To sign as Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Day Month Year

	/	/
--	---	---

Privacy Clause: Automic Pty Ltd (ACN 152 260 814) trading as Automic Registry Services (Automic) advises that Chapter 2C of the *Corporations Act 2001* requires information about you as a securityholder (including your name, address and details of the securities you hold) to be included in the public register of the entity in which you hold securities. Primarily, your personal information is used in order to provide a service to you. We may also disclose the information that is related to the primary purpose and it is reasonable for you to expect the information to be disclosed. You have a right to access your personal information, subject to certain exceptions allowed by law and we ask that you provide your request for access in writing (for security reasons). Our privacy policy is available on our website – www.automic.com.au